With advances in immunosuppressive therapy, there have been significant improvements in
acute rejection rates and short‐term allograft survival in kidney transplant recipients …

ABSTRACT Introduction: Tacrolimus (Tac) is effective in preventing acute rejection but has
considerable toxicity and inter-individual variability in pharmacokinetics and …

Tacrolimus, widely used to prevent acute rejection following solid‐organ transplantation, has
become the cornerstone of immunosuppressive therapy after kidney transplantation. More …

Abstract Background Cytochrome P450 (CYP) 3A4 and 3A5 are major isoforms involved in
the metabolism of tacrolimus, with the CYP3A5 gene being more polymorphic. It is …

Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose
to achieve therapeutic exposure compared with nonexpressers. This randomized‐controlled …

Tacrolimus is metabolized by CYP3A4 and CYP3A5 and is characterized by a narrow
therapeutic index and highly variable pharmacokinetics. This cross‐sectional study in 59 …

Background: Tacrolimus is established as immunosuppressant after kidney transplantation.
Polymorphism of the cytochrome P450 3A5 (CYP3A5) gene contributes significantly to …

Kidney transplantation has become the treatment of choice for patients with end-stage renal
disease because of better surgical techniques and the availability of more powerful …

Aims Although cytochromeP450 (CYP) 3A5 gene polymorphism affects personalized
tacrolimus doses, there is no consensus as to whether CYP3A5 genotypes should be …

Background Optimal management of immunosuppression in kidney transplantation requires
a delicate balance of efficacy and toxicity. Tacrolimus (TAC) dose requirements are …